Gerald Lee, MD; Stanley Fineman, MD; Tim Chow, MD; Disclosures
To download the mp3 file, right click on the player and select Save audio as.
Interested in claiming CME for this episode? Click here
Show Notes
Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology. For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Today we are joined by Dr. Tim Chow, an assistant professor at UT Southwestern and an assistant editor of Allergy Watch. We will be reviewing the May/June 2024 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
- CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.
- Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants
- IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Speaker Disclosures back to top
Gerald Lee, MD
Speaker: Novartis
Stanley Fineman, MD
No relevant financial relationships with ineligible companies to disclose
Tim Chow, MD
No relevant financial relationships with ineligible companies to disclose